Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIGNATURE: MEK162 in pathway-activated tumors
NCT01885195Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2013
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of binimetinib in solid tumor and hematologic malignancy, sponsored by Pfizer. Primary endpoints: Clinical Benefit Rate for Solid Tumors at Week 16, Clinical Benefit Rate for Multiple Myeloma at Week 16 and 1 more. Started Oct 2013; status: completed.
02
Drugs
binimetinib
03
Conditions
solid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT01885195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01885195.